Examples are early clinical trials assessing 7 + 3 chemotherapy in combination with ziftomenib or bleximenib as first-line treatment, resulting in CR/CRh rates of 91% and 81%, in younger patients with KMT2A-rearranged or NPM1-mutated AML [109, 110]. This evidence concerns the gene KMT2A and acute myeloid leukemia.